Literature DB >> 8495813

Murine insulinoma cell line with normal glucose-regulated insulin secretion.

S Efrat1, M Leiser, M Surana, M Tal, D Fusco-Demane, N Fleischer.   

Abstract

Pancreatic beta TC lines derived from insulinomas arising in transgenic mice expressing SV40 Tag under control of the insulin promoter manifest a differentiated beta-cell phenotype and secrete insulin in response to glucose. Previously reported beta TC lines respond to subphysiological extracellular glucose levels compared with normal beta-cells. Recently, several beta TC lines were developed with normal glucose-regulated insulin secretion from insulinomas obtained by breeding of the RIP-Tag transgene from the original C57BI/6 mouse strain into the C3HeB/FeJ strain. One of these beta TC lines, beta TC7, was characterized in detail. Beta TC7 cells express GLUT2 and have levels of glucokinase and hexokinase activity similar to those of normal islets. As a result these cells exhibit a normal glucose concentration dependency for glycolysis and insulin secretion, thus representing an accurate model of beta-cell function. On continuous propagation in culture, beta TC7 cells acquired a response to lower extracellular glucose levels. This change was associated with a fourfold increase in hexokinase activity, without significant changes in glucokinase activity and glucose uptake rates. These findings suggest an important role for glucose phosphorylation rates in regulation of the beta-cell insulin secretory response to glucose.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8495813     DOI: 10.2337/diab.42.6.901

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  15 in total

Review 1.  [Insulin producing cells as therapy in diabetes mellitus].

Authors:  W J Schnedl; H E Hohmeier; C B Newgard
Journal:  Naturwissenschaften       Date:  1996-01

2.  Rat islet cell lines produced by retroviral transduction of SV40 T antigen.

Authors:  H C Kaung; C Wang; S Xu; J W Jacobberger; W Chen
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-04       Impact factor: 2.416

Review 3.  Concise review: in search of unlimited sources of functional human pancreatic beta cells.

Authors:  Raphael Scharfmann; Latif Rachdi; Philippe Ravassard
Journal:  Stem Cells Transl Med       Date:  2012-12-19       Impact factor: 6.940

4.  Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet beta-cells and enhances insulin secretion.

Authors:  C M Buchanan; A R Phillips; G J Cooper
Journal:  Biochem J       Date:  2001-12-01       Impact factor: 3.857

5.  Role of ATP and Pi in the mechanism of insulin secretion in the mouse insulinoma betaTC3 cell line.

Authors:  K K Papas; R C Long; I Constantinidis; A Sambanis
Journal:  Biochem J       Date:  1997-09-15       Impact factor: 3.857

Review 6.  The supply chain of human pancreatic β cell lines.

Authors:  Raphael Scharfmann; Willem Staels; Olivier Albagli
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

7.  Finally! A human pancreatic β cell line.

Authors:  Gordon C Weir; Susan Bonner-Weir
Journal:  J Clin Invest       Date:  2011-08-25       Impact factor: 14.808

8.  Activation of a cAMP-regulated Ca(2+)-signaling pathway in pancreatic beta-cells by the insulinotropic hormone glucagon-like peptide-1.

Authors:  G G Holz; C A Leech; J F Habener
Journal:  J Biol Chem       Date:  1995-07-28       Impact factor: 5.157

9.  Pancreatic beta cells cultured from individual preneoplastic foci in a multistage tumorigenesis pathway: a potentially general technique for isolating physiologically representative cell lines.

Authors:  F Radvanyi; S Christgau; S Baekkeskov; C Jolicoeur; D Hanahan
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

10.  Towards the development of a bioartificial pancreas: immunoisolation and NMR monitoring of mouse insulinomas.

Authors:  A Sambanis; K K Papas; P C Flanders; R C Long; H Kang; I Constantinidis
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.